Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2018 2
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic properties of non-vaccinia poxviruses.
Ricordel M, Foloppe J, Pichon C, Findeli A, Tosch C, Cordier P, Cochin S, Quémeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P. Ricordel M, et al. Among authors: findeli a. Oncotarget. 2018 Nov 13;9(89):35891-35906. doi: 10.18632/oncotarget.26288. eCollection 2018 Nov 13. Oncotarget. 2018. PMID: 30542506 Free PMC article.
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P. Foloppe J, et al. Among authors: findeli a. Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31011628 Free PMC article.
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators.
Gallardo F, Schmitt D, Brandely R, Brua C, Silvestre N, Findeli A, Foloppe J, Top S, Kappler-Gratias S, Quentin-Froignant C, Morin R, Lagarde JM, Bystricky K, Bertagnoli S, Erbs P. Gallardo F, et al. Among authors: findeli a. Biomedicines. 2020 Nov 26;8(12):543. doi: 10.3390/biomedicines8120543. Biomedicines. 2020. PMID: 33256205 Free PMC article.
Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.
Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P. Ricordel M, et al. Among authors: findeli a. Cancers (Basel). 2018 Jul 10;10(7):231. doi: 10.3390/cancers10070231. Cancers (Basel). 2018. PMID: 29996551 Free PMC article.
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G. Martin P, et al. Among authors: findeli a. Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26. Gut. 2015. PMID: 25429051 Free PMC article.
Feedback